Garrido-Laguna, I., Wolpin, B. M., Park, W., Azad, N. S., Spira, A. I., Starodub, A., Sommerhalder, D., Punekar, S. R., Herzberg, B., Barve, M. A., Pelster, M., Valerin, J. B., Hecht, J. R., Vora, R., Hegde, A. M., Gustafson, C., Tao, L., Kar, S., Lin, K. K., Hong, D. S. (2025). Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.722